HYDROCORTISONE | N009176 | PFIZER GLOBAL RESEARCH DEVELOPMENT
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | National Cancer Institute (NCI) | 244 | 2021-10-05 → 2026-12-31 | |
| Phase 1/2 | Active | St. Jude Children's Research Hospital | 50 | 2016-01-29 → 2031-10 | |
| Phase 2 | Active | Children's Oncology Group | 78 | 2024-01-08 → 2027-12-31 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 847 | 2014-10-04 → 2027-09-16 | |
| Phase 1/2 | Active | St. Jude Children's Research Hospital | 35 | 2022-08-25 → 2027-02 | |
| Phase 3 | Active | Dana-Farber Cancer Institute | 560 | 2017-03-03 → 2034-11 | |
| Phase 2 | Active | St. Jude Children's Research Hospital | 25 | 2023-01-17 → 2028-08 | |
| Phase 2 | Active | St. Jude Children's Research Hospital | 206 | 2017-06-15 → 2027-06 | |
| Phase 2 | Active | National Hospital Organization Nagoya Medical Center | 60 | 2017-04-18 → 2033-03-31 | |
| Early Phase 1 | Active | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 5 | 2020-02-09 → 2026-06-24 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
14 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.